Marisa McGinley (Mellen Center, Cleveland Clinic Main Campus, Ohio, USA) shared her expert insights with us on the most significant developments in the treatment of multiple sclerosis (MS) over the past year.
Questions
1. What are the current unmet needs in multiple sclerosis (MS) treatment? (0:04)
2. What have been the most important recent advances in the treatment of primary progressive MS? (0:42)
3. Which patients with secondary progressive MS are most likely to benefit from siponimod? (1:11)
4. When should we begin treatment for progressive MS? (2:36)
5. How can quantitative MRI data be used in routine MS clinical practice? (3:51)
6. How important are patient reported outcomes in clinical decision-making? (5:18)
Speaker disclosures: Marisa McGinley serves as a consultant for Genzyme and Genentech.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
